keyword
MENU ▼
Read by QxMD icon Read
search

Chronic idiopathic urticaria

keyword
https://www.readbyqxmd.com/read/29760614/eradication-of-helicobacter-pylori-as-add-on-therapy-has-a-significant-but-temporary-influence-on-recovery-in-chronic-idiopathic-urticaria-a-placebo-controlled-double-blind-trial-in-the-polish-population
#1
Robert Pawłowicz, Krzysztof Wytrychowski, Bernard Panaszek
Introduction: The infectious factor like Helicobacter pylori (HP) has been thought to trigger the vicious circle of chronic idiopathic urticaria (CIU), therefore its eradication could modify the course of the disease. Aim: To reveal the influence of HP eradication on CIU clinical course. Material and methods: Sixty-four CIU patients, receiving fexofenadine, as the basic treatment, took part in the research, divided into 3 groups: HP patients treated by eradication, HP patients receiving placebo, and patients without bacteria...
April 2018: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29682366/whole-exome-sequencing-and-molecular-modeling-of-a-missense-variant-in-tnfaip3-that-segregates-with-disease-in-a-family-with-chronic-urticaria-and-angioedema
#2
Antoneicka L Harris, Patrick R Blackburn, John E Richter, Jennifer M Gass, Thomas R Caulfield, Ahmed N Mohammad, Paldeep S Atwal
Chronic urticaria is a common condition characterized by recurrent hives lasting several weeks or months and is usually idiopathic. Approximately half of the individuals with chronic urticaria will present with episodes of angioedema that can be severe and debilitating. In this report, we describe a 47-year-old Hispanic male who presented initially for an evaluation of chronic hives following hospitalization due to hive-induced anaphylaxis. The individual had a history significant for urticaria and angioedema beginning in his early 30s...
2018: Case Reports in Genetics
https://www.readbyqxmd.com/read/29663342/associations-of-chronic-urticaria-with-atopic-and-autoimmune-comorbidities-a-nationwide-population-based-study
#3
Hsien-Yi Chiu, Chih-Hsin Muo, Fung-Chang Sung
BACKGROUND: Most cases of chronic urticaria (CU) are idiopathic. Circumstantial evidence suggests that some CU cases have an autoimmune pathogenesis. Previous research indicates that a substantial percentage of patients with CU have an atopic background. OBJECTIVES: This study aims to examine the association between CU, and atopic and autoimmune diseases. METHODS: This population-based retrospective cohort study identified 9,332 patients with CU and 37,328 controls matched for age, sex, and number of dermatological clinic visits from the Taiwan National Health Insurance Research Database for 2004-2009...
April 16, 2018: International Journal of Dermatology
https://www.readbyqxmd.com/read/29611440/new-biologics-for-allergic-diseases
#4
Laurie A Manka, Michael E Wechsler
Allergic conditions such as asthma and atopic dermatitis have a high prevalence but represent a heterogeneous group of diseases despite similar clinical presentation and underlying pathophysiology. A better understanding of the phenotypes and endotypes of these diseases has driven rapid development of biologic medications targeting many steps of the inflammatory pathways. Areas covered: There are 2 major inflammatory pathways that drive allergic diseases: Type-2 (Th-2) inflammation and non-type 2 inflammation...
April 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29567359/validity-and-responsiveness-of-the-urticaria-activity-and-impact-measure-u-aim-a-new-patient-reported-tool
#5
Marcus Maurer, Susan D Mathias, Ross D Crosby, Yamina Rajput, James L Zazzali
BACKGROUND: Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), may produce hives, itch, and angioedema. The Urticaria Activity and Impact Measure (U-AIM) is a newly developed 9-item patient-reported measure designed for use in routine clinical practice to assess CSU activity and impact over the previous 7 days. OBJECTIVE: To evaluate validity, responsiveness, and clinically meaningful change of the U-AIM. METHODS: Data from a 24-week open-label single-arm period of a randomized, placebo-controlled study of omalizumab were used to assess the psychometric properties of U-AIM items for itch, hives, and angioedema...
March 19, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29514728/health-care-burden-and-treatment-patterns-in-commercially-insured-children-with-chronic-idiopathic-spontaneous-urticaria-a-real-world-study-in-the-united-states
#6
Paul Williams, Abhishek Kavati, Dominic Pilon, Yongling Xiao, Maryia Zhdanava, Maria-Magdalena Balp, Patrick Lefebvre, Benjamin Ortiz, Vivian Hernandez-Trujillo
BACKGROUND: Chronic idiopathic urticaria (CIU)/spontaneous urticaria (CSU) is defined by the presence of wheals, angioedema, or both for ≥6 weeks, with or without an identifiable trigger. Real-world health care data among children with CIU/CSU remain scarce. OBJECTIVES: To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (<12 years old) and to compare these with pediatric patients without CIU/CSU...
May 19, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29458456/real-world-use-of-omalizumab-in-patients-with-chronic-idiopathic-spontaneous-urticaria-in-the-united-states
#7
Jacqueline Eghrari-Sabet, Ellen Sher, Abhishek Kavati, Dominic Pilon, Maryia Zhdanava, Maria-Magdalena Balp, Patrick Lefebvre, Benjamin Ortiz, Jonathan A Bernstein
BACKGROUND: Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014. OBJECTIVE: This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients with CIU/CSU. METHODS: Patients with CIU/CSU (ages ≥12 years) initiated on omalizumab (index date) with ≥12 months of pre- and postindex data were identified in the an insurance claims data base (January 1, 2013, to July 31, 2016)...
May 7, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29457982/discovery-of-gdc-0853-a-potent-selective-and-noncovalent-bruton-s-tyrosine-kinase-inhibitor-in-early-clinical-development
#8
James J Crawford, Adam R Johnson, Dinah L Misner, Lisa D Belmont, Georgette Castanedo, Regina Choy, Melis Coraggio, Liming Dong, Charles Eigenbrot, Rebecca Erickson, Nico Ghilardi, Jonathan Hau, Arna Katewa, Pawan Bir Kohli, Wendy Lee, Joseph W Lubach, Brent S McKenzie, Daniel F Ortwine, Leah Schutt, Suzanne Tay, BinQing Wei, Karin Reif, Lichuan Liu, Harvey Wong, Wendy B Young
Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here we disclose the discovery and preclinical characterization of a potent, selective, and noncovalent Btk inhibitor currently in clinical development...
March 22, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29431522/posttraumatic-stress-disorder-emotional-suppression-and-psychiatric-co-morbidity-in-patients-with-chronic-idiopathic-urticaria-a-moderated-mediation-analysis
#9
Man Cheung Chung, Christine Symons, Jane Gilliam, Edward R Kaminski
BACKGROUND: There is evidence suggesting that posttraumatic stress disorder (PTSD) symptom severity and CIU severity are linked and partially mediated by the high-anxious defense mechanism. What is unclear is whether emotional suppression, as a defense serving the opposite purpose for high-anxious defense, can also act as a mediator and whether this mediational effect is partly influenced by time since trauma and trauma type. AIMS: To investigate whether emotional suppression mediated the links between PTSD and CIU symptom severities, and PTSD and psychiatric co-morbid symptom severities...
February 12, 2018: Journal of Mental Health
https://www.readbyqxmd.com/read/29431518/effectiveness-of-omalizumab-in-adolescent-and-adult-patients-with-chronic-idiopathic-spontaneous-urticaria-a-systematic-review-of-real-world-evidence
#10
Jonathan A Bernstein, Abhishek Kavati, Michael D Tharp, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck, Ivo Abraham
Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological condition characterized by itchy wheals and/or angioedema of continuous or intermittent duration of ≥6 weeks with a high burden of disease and impact on quality of life. Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of IgE to high affinity receptors, and is approved for the CIU/CSU indication. The objective of this systematic review was to evaluate and synthesize the evidence on the real-world effectiveness of omalizumab in CIU/CSU in daily clinical practice...
April 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29429043/treatment-patterns-healthcare-resource-utilization-and-spending-among-medicaid-enrolled-children-with-chronic-idiopathic-spontaneous-urticaria-in-the-united-states
#11
Paul V Williams, Abhishek Kavati, Dominic Pilon, Yongling Xiao, Maryia Zhdanava, Maria-Magdalena Balp, Patrick Lefebvre, Benjamin Ortiz, Vivian Hernandez-Trujillo
INTRODUCTION: Few studies have described chronic idiopathic/spontaneous urticaria (CIU/CSU) healthcare burden in adults, while this information remains largely unknown in children. We aimed to describe treatment patterns, healthcare resource utilization (HRU), and costs in CIU/CSU pediatric patients, as well as to compare HRU and costs in CIU/CSU and CIU/CSU-free pediatric patients. METHODS: Medicaid claims from four states (09/01/2013-03/31/2016) were used to identify patients less than 12 years old...
March 2018: Dermatology and Therapy
https://www.readbyqxmd.com/read/29406838/real-world-characteristics-and-treatment-patterns-in-patients-with-urticaria-initiating-omalizumab-in-the-united-states
#12
Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Liya Wang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
BACKGROUND: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) in patients aged 12 years or older with persistent hives that are not adequately controlled by H1 antihistamines. While its safety and efficacy in CIU patients have been evaluated in multiple clinical trials, real-world use of omalizaumab in CIU has not been well characterized. OBJECTIVE: To assess demographics, clinical characteristics, and treatment patterns of CIU patients who initiated omalizumab to better understand the usage of this agent in CIU management in the real world...
December 19, 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29350016/biomarkers-of-treatment-efficacy-in-patients-with-chronic-spontaneous-urticaria
#13
M Sánchez-Borges, A Capriles-Hulett, F Caballero-Fonseca, L González-Aveledo
Background. Currently there are no biomarkers useful to predict the future evolution and the therapeutic response in patients with chronic spontaneous urticaria (CSU). Objective. To review the available information on biomarkers that might be applied for the follow up of the response to guideline recommended therapies for CSU. Methods. A review of the medical literature on CSU potential clinical and laboratory biomarkers in PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, chronic spontaneous urticaria, antihistamines (AHs), omalizumab (OMA), cyclosporine (CyA), and treatment...
January 2018: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29315922/the-use-of-omalizumab-in-allergen-immunotherapy
#14
REVIEW
J A Dantzer, R A Wood
Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy...
March 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29208545/il-24-is-a-common-and-specific-autoantigen-of-ige-in-patients-with-chronic-spontaneous-urticaria
#15
Oliver Schmetzer, Elisa Lakin, Fatih A Topal, Patricia Preusse, Denise Freier, Martin K Church, Marcus Maurer
BACKGROUND: The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms. OBJECTIVE: We sought to identify autoallergic targets of IgE in patients with CSU. METHODS: Serum samples of patients with CSU together with those of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for IgE autoantibodies by using an array of more than 9000 proteins...
December 5, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29132956/the-xtend-ciu-study-long-term-use-of-omalizumab-in-chronic-idiopathic-urticaria
#16
Marcus Maurer, Allen Kaplan, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Thomas B Casale
No abstract text is available yet for this article.
March 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29064325/real-world-treatment-patterns-and-outcomes-of-omalizumab-use-in-patients-with-chronic-idiopathic-urticaria
#17
Liya Wang, Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
OBJECTIVE: To examine treatment patterns, treatment response, and demographic and clinical characteristics of patients with chronic idiopathic urticaria (CIU) newly initiated on omalizumab therapy in real-world practice in the US. METHODS: This retrospective observational cohort study used US claims data from the HealthCore Integrated Research Database (HIRD® ) augmented with medical record data to identify CIU patients newly-treated with omalizumab (≥4 omalizumab claims within 6 months of initial claim; index date = first omalizumab claim date) between March 21, 2014 and October 31, 2015 and with ≥6 months pre- and ≥12 months post-index health plan eligibility...
January 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29037993/omalizumab-response-in-patients-with-chronic-idiopathic-urticaria-insights-from-the-xtend-ciu-study
#18
Thomas B Casale, Patrick H Win, Jonathan A Bernstein, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Evgeniya N Antonova, Thomas Murphy, Mark D Scarupa, Howard Sofen, Allen Kaplan
No abstract text is available yet for this article.
April 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28888844/recurrence-of-chronic-urticaria-incidence-and-associated-factors
#19
Julie K Kim, Daniel Har, L Steven Brown, David A Khan
BACKGROUND: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). OBJECTIVES: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. METHODS: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed...
March 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28852410/management-of-chronic-spontaneous-urticaria-csu-a-treat-to-target-approach-using-a-patient-reported-outcome
#20
Hermenio Lima, Melinda Gooderham, Jan Dutz, Charles Lynde, Hugo Chapdelaine, Anne Ellis, Martin Gilbert, Vincent Ho, Kim Papp, Yves Poulin, Gordon Sussman
BACKGROUND: Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging...
2017: Allergy, Asthma, and Clinical Immunology
keyword
keyword
12612
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"